Nykode Therapeutics AS (CHIX:NYKDO) Total Equity: kr845.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NYKDO Nykode Therapeutics AS CHIX:NYKDO
48 GF Score
Price kr18.69
GF Value kr42.67
! 1 Warning Sign
View Full Analysis

What is Nykode Therapeutics AS Total Equity?

Nykode Therapeutics AS CHIX:NYKDO 48 Total Equity is kr845.25 Mil as of Mar. 2026. GuruFocus rates CHIX:NYKDO with a GF Score™ of 48/100 and a GF Value™ of kr42.67. The stock has 1 warning sign investors should review.

Nykode Therapeutics AS's total equity for the quarter that ended in Mar. 2026 was kr845.25 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nykode Therapeutics AS Total Equity Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Total Equity Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 1,742.83 1,551.35 1,806.68 1,528.38 925.16

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,430.31 1,033.00 986.88 925.16 845.25
CHIX:NYKDO
48GF Score
Nykode Therapeutics AS CHIX:NYKDO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nykode Therapeutics AS's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1010.235-85.08
=925.16

Nykode Therapeutics AS's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=906.633-61.38
=845.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr845.25 Mil mean?
Nykode Therapeutics AS (CHIX:NYKDO) has a Total Equity of kr845.25 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Total Equity too high?
Nykode Therapeutics AS's current Total Equity is kr845.25 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Total Equity compare to VRTX and REGN?
Nykode Therapeutics AS's Total Equity of kr845.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Total Equity is kr845.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Nykode Therapeutics AS (CHIX:NYKDO) has a current Total Equity of kr845.25 Mil. The stock's GF Value™ is kr42.67, compared to a current price of kr18.69 — trading 56.2% below its estimated fair value. The current Total Equity is kr845.25 Mil. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nykode Therapeutics AS (CHIX:NYKDO), the current Total Equity is kr845.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (CHIX:NYKDO) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of kr18.69 is trading 56.2% below its estimated GF Value™ of kr42.67.

Key valuation signals for CHIX:NYKDO:

  • Total Equity: kr845.25 Mil
  • GF Value™: kr42.67 vs. price of kr18.69 (56.2% below fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the CHIX:NYKDO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score

Get the complete analysis for CHIX:NYKDO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.69
Price
kr42.67
GF Value